Session highlights
Educational Symposium
MFN Meets IRP: How U.S. Pricing Reform Rewires Global Market Interdependencies
Our educational symposium explored the ripple effects of U.S. pricing reform — including Most Favored Nation (MFN) and International Reference Pricing (IRP) models — on global market access strategies.
Panelists examined how evolving U.S. policy is reshaping pricing interdependencies across markets and discussed practical approaches for biopharma organizations navigating this shifting landscape. Click below to access the symposium recording.
Panelists examined how evolving U.S. policy is reshaping pricing interdependencies across markets and discussed practical approaches for biopharma organizations navigating this shifting landscape. Click below to access the symposium recording.
Partnership group forum
The business of evidence: HEOR for C-suite decision making
This forum brought together senior HEOR and commercial leaders to discuss how health economics and outcomes research can be elevated from a technical function to a strategic driver of C-suite decision making. Speakers shared perspectives on demonstrating the business value of evidence generation, aligning HEOR investments with enterprise priorities, and positioning evidence teams as indispensable partners in commercialization strategy.
Moderator: Christopher M. Blanchette, Novo Nordisk
Speakers: Paulo Carita, Sanofi; Jaime Rubin Cahill, Vertex Pharmaceuticals; Tommy Bramley, Cencora; Simu Thomas, Alexion
Moderator: Christopher M. Blanchette, Novo Nordisk
Speakers: Paulo Carita, Sanofi; Jaime Rubin Cahill, Vertex Pharmaceuticals; Tommy Bramley, Cencora; Simu Thomas, Alexion
Podium session
Novel Copula-Based Method for Cross-Country EQ-5D Utility Value Conversion
International health technology assessments often require EQ-5D utility values to be converted across country-specific tariffs, yet no standard methodology currently exists. This study aimed to develop and validate a novel approach for converting UK EQ-5D-3L values to country-specific equivalents by repurposing the intermediate caliper-matching algorithm from the NICE-recommended 3L/5L mapping copula model (Hernandez-Alava, 2020).
Authors/speakers: Chris Poole, PhD, Dir, Cencora; Rashad Carlton, PharmD, MSPH, Sr Dir, Cencora; Paul Turner, PhD, Dir, Cencora; Natalia Hawken, Merck
Authors/speakers: Chris Poole, PhD, Dir, Cencora; Rashad Carlton, PharmD, MSPH, Sr Dir, Cencora; Paul Turner, PhD, Dir, Cencora; Natalia Hawken, Merck
Poster session
Evaluating the Performance of a Generative Artificial Intelligence Chatbot for Assessing Systematic Literature Reviews Using the Preferred Reporting Items for Systematic Reviews and Meta-analyses 2020 Checklist
Authors/Presenters: Maria Arregui, PhD, Assistant Dir, Cencora; Evelyn Gomez-Espinosa PhD, Asst Dir, Cencora; Erika Wissinger, PhD, Sr Dir, Cencora; Maria Koufopoulou MSc, Dir, Cencora
Authors/Presenters: Maria Arregui, PhD, Assistant Dir, Cencora; Evelyn Gomez-Espinosa PhD, Asst Dir, Cencora; Erika Wissinger, PhD, Sr Dir, Cencora; Maria Koufopoulou MSc, Dir, Cencora
With team across North America, Europe, and Japan, we blend global reach with local expertise
3,000
Consultants worldwide
30+
Global markets covered
235+
Brands represented
Cencora partners with ISPOR to advance HEOR
We are thrilled to announce Cencora's partnership with ISPOR in their new Corporate Partnership Program! This collaboration aligns with our commitment to advancing health economics and outcomes research. Together, we'll drive innovation, enhance global health outcomes, and strengthen the HEOR community.
Catch up on our latest insights
Catch up on the latest edition of HTA Quarterly
In this edition, we discuss the risks of relying on immature data for survival projections in oncology and the importance of selecting robust models to guide HTA decisions. We also explore key challenges and developments in HTA within the UK and Germany, including the impact of limited clinical evidence on NICE appraisals, with strategies to improve submission outcomes, and recent updates to Germany’s AMNOG dossier requirements, highlighting the evolution to trend-based estimates to better align benefit assessments with statutory health insurance patient populations.
Navigating the Canadian reimbursement landscape
Despite perceptions of a universal healthcare system, Canada’s medication reimbursement relies on both public and private payers, impacting market access for new therapies. In this video, Beth Koster, Director, Health Economics & Outcomes Research (HEOR), shares considerations for market access, including the need for early strategic planning and comprehensive evidence collection.
